Fig. 1

Olaparib and Oligo-Fucoidan cooperatively promote TNBC cell death. A Cell viability was examined following olaparib (0–50 μM) treatment for 24 h and was examined by WST-1 assays. B The levels of PARP, cleaved PARP (Asp214), p21, γ-H2AX, p-AMPK (Thr172), AMPK and Rad51 were analyzed after olaparib (0–50 μM) treatment for 48 h. C Cell viability was analyzed by WST-1 assays after olaparib (50 μM) and/or Oligo-Fucoidan (400 μg/ml) treatment for 24 h. D Cell cycle profiling was performed after olaparib (50 μM) and/or Oligo-Fucoidan (400 μg/ml) administration for 48 h. E Histograms reveal the cell cycle patterns and comparisons between experimental settings. One-way ANOVA with Duncan’s test was used to calculate statistical significance (A, C, E)